立即開始
DiastoAle

Missed Approval But Q2 Looks Promsing

看多
United Therapeutics Corporation (NASDAQ:UTHR)  
DiastoAle  
NASDAQ:UTHR   United Therapeutics Corporation
Trend Analysis
0
0
trendanalysis
More things down the pipeline to come, and this company is making tons of money. This price is going to fill the gap for sure and stay above 200 in Q2.
免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。